TDMS Study 93020-06 Pathology Tables

NTP Experiment-Test: 93020-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          DIISOPROPYLCARBODIIMIDE (DIC)                               Date: 01/10/01
Route: SKIN APPLICATION                                                                                           Time: 08:32:09
                                                         Final #1/Mice
       Facility:  BIORELIANCE
       Chemical CAS #:  693-13-0
       Lock Date:  02/24/00
       Cage Range:  All
       Reasons For Removal:    All
       Removal Date Range:     All
       Treatment Groups:       Include All
a  Number of animals examined microscopically at site and number of animals with lesion
                                                              Page   1
NTP Experiment-Test: 93020-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          DIISOPROPYLCARBODIIMIDE (DIC)                               Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:32:09  
____________________________________________________________________________________________________________________________________
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      4.38         8.75         17.5         35 MG/KG     70 MG/KG        
                                                   CONTROL      MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY                                                                                                                 
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
  Survivors                                                                                                                         
    Terminal Sacrifice                                15           15           15           15           15           15           
  Animals Examined Microscopically                    15           15           15           15           15           15           
____________________________________________________________________________________________________________________________________
 ALIMENTARY SYSTEM                                                                                                                  
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 CARDIOVASCULAR SYSTEM                                                                                                              
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 ENDOCRINE SYSTEM                                                                                                                   
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 GENERAL BODY SYSTEM                                                                                                                
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 GENITAL SYSTEM                                                                                                                     
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 HEMATOPOIETIC SYSTEM                                                                                                               
   Lymph Node, Mandibular                             (15)         (15)         (15)         (14)         (15)         (15)         
                                                             Page   2                                                               
NTP Experiment-Test: 93020-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          DIISOPROPYLCARBODIIMIDE (DIC)                               Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:32:09  
____________________________________________________________________________________________________________________________________
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      4.38         8.75         17.5         35 MG/KG     70 MG/KG        
                                                   CONTROL      MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont                                                                                                         
      Hemangioma                                                                                           1 (7%)                   
____________________________________________________________________________________________________________________________________
 INTEGUMENTARY SYSTEM                                                                                                               
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 MUSCULOSKELETAL SYSTEM                                                                                                             
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 NERVOUS SYSTEM                                                                                                                     
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 RESPIRATORY SYSTEM                                                                                                                 
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 SPECIAL SENSES SYSTEM                                                                                                              
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 URINARY SYSTEM                                                                                                                     
   None                                                                                                                             
                                                             Page   3                                                               
NTP Experiment-Test: 93020-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          DIISOPROPYLCARBODIIMIDE (DIC)                               Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:32:09  
____________________________________________________________________________________________________________________________________
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      4.38         8.75         17.5         35 MG/KG     70 MG/KG        
                                                   CONTROL      MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY                                                                                                                       
   Total Animals with Primary Neoplasms (b)                                                             1                           
     Total Primary Neoplasms                                                                            1                           
   Total Animals with Benign Neoplasms                                                                  1                           
     Total Benign Neoplasms                                                                             1                           
   Total Animals with Malignant Neoplasms                                                                                           
     Total Malignant Neoplasms                                                                                                      
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                             Page   4                                                               
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------